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Abstract
Background:  Movement disorders are frequent features of  prionopathies. However, their prevalence and onset remain poorly described.
Methods:  We performed a systematic review of  case reports and case series of  pathologically- and genetically confirmed prionopathies. Timing of  symptom and 
movement disorder onset were documented. Continuous variables were compared between two groups using the Wilcoxon rank sum test and between multiple 
groups using Kruskal–Wallis test. Categorical variables were compared using Fisher’s exact test.
Results:  A total of  324 cases were included in this analysis. Movement disorders were a common feature at the onset of  symptoms in most prionopathies. Gait 
ataxia was present in more than half  of  cases in all types of  prionopathies. The prevalence of  limb ataxia (20%) and myoclonus (24%) was lower in Gerstmann–
Sträussler–Scheinker disease compared to other prionopathies (p ≤ 0.004). Myoclonus was common but often a later feature in sporadic Creutzfeldt–Jakob disease 
(2 months before death). Chorea was uncommon but disproportionately prevalent in variant Creutzfeldt–Jakob disease (30% of  cases; p < 0.001). In genetic 
Creutzfeldt–Jakob disease, E200K PRNP carriers exhibited gait and limb ataxia more often when compared to other mutation carriers.
Discussion:  Movement disorders are differentially present in the course of  the various prionopathies. The movement phenomenology and appearance are asso-
ciated with the type of  prion disease and the PRNP genotype and likely reflect the underlying pattern of  neurodegeneration. Reliance on myoclonus as a diagnostic 
feature of  sporadic Creutzfeldt–Jakob disease may delay its recognition given its relatively late appearance in the disease course.
Keywords: Prion, Creutzfeldt–Jakob, Gerstmann–Sträussler–Scheinker, fatal familial insomnia, movement disorders, ataxia, myoclonus
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Introduction
Human prionopathies are rapidly progressive neurodegenerative dis-
orders of  the central nervous system characterized by accumulation of  
the pathogenic, misfolded isoform of  the endogenous cell-surface pri-
on-related protein (PrP), known as prions. Prionopathies can be classi-
fied by their mode of  transmission: Sporadic prion diseases include 
sporadic Creutzfeldt–Jakob (sCJD) and variably protease-sensitive pri-
onopathy (VPSPr); acquired prion diseases include variant Creutzfeldt–
Jakob disease (vCJD) and iatrogenic Creutzfeldt–Jakob disease (iCJD); 
genetic prion disorders include genetic Creutzfeldt–Jakob disease 
(gCJD), Gerstmann–Sträussler–Scheinker disease (GSS), and fatal 
familial insomnia (FFI).
The neurologic signs and symptoms of  prionopathies reflect the ana-
tomical pattern of  neurodegeneration caused by prions. Multiple fac-
tors influence the clinical presentation, including the type of  prion 
disorder, the methionine–valine polymorphism in codon 129, and the 
presence of  other pathogenic mutations in the prion protein gene 
(PRNP).
Although prionopathies are traditionally associated with rapidly pro-
gressive dementia, movement disorders are often present, sometimes 
representing the initial manifestation or the only symptom. However, 
the diagnostic and prognostic utility of  movement phenomenology in 
suspected prionopathies remains undetermined. Given the rarity of  
prion diseases and the substantial heterogeneity of  their presentation, 
we reviewed published case reports and case series to describe the phe-
notypic spectrum and evaluate whether differences in semiology and 
timing of  appearance can serve as distinguishing features.
Methods
Search strategy and data extraction
We performed a systematic review of  prionopathies published from 
January 1970 until February 2019. We searched articles on PubMed 
without language restriction using the following terms: prion or Creutzfeldt–
Jakob or Jakob–Creutzfeldt or CJD or protease-sensitive prionopathy or variant CJD 
or iatrogenic CJD or familial CJD or genetic CJD or fatal familial insomnia or 
Gerstmann–Sträussler–Scheinker. This strategy yielded 23,044 results. The 
titles were reviewed for eligibility criteria, specifically case reports and 
case series. Abstracts were reviewed as needed. We included only arti-
cles that contained: (1) well-documented patients; (2) report of  time 
between symptom onset and death; (3) sCJD, vCJD, iCJD, and VPSPr 
confirmed by autopsy, or gCJD, FFI, and GSS confirmed by either 
genetic or autopsy evaluation. We also excluded articles with incomplete 
or absent disease phenomenology (Supplementary Figure S1).
All subjects from articles that met inclusion criteria were included in 
a database. From these articles, we extracted demographic data (e.g., 
age, gender, and disease duration), chronology of  symptom onset (e.g., 
cognitive or behavioral impairment, abnormal movements, sleep 
impairment, autonomic dysfunction, and others) and onset of  move-
ment disorders, measured in months before death, and the ratio of  these 
values to total disease duration. The specific genetic mutations were 
documented for the genetic prionopathies gCJD, FFI, and GSS.
Statistical analysis
Each subject extracted was defined to be a unit for analysis, and no 
weight was assigned to any study. Continuous data were expressed by 
median with interquartile range (IQR), while categorical data were 
expressed by frequency and percentage. Due to unequal and varying 
group sizes, all statistical analyses were conducted using nonparametric 
tests. Continuous variables were compared between two groups using 
Wilcoxon rank sum test and between multiple groups using the Kruskal–
Wallis test. Categorical variables were compared using Fisher’s exact 
test. In the case of  multiple groups with low cell frequencies, chi square 
was used. Symptom/total disease duration ratio was compared with 
one-way ANOVA and presented with mean and standard deviation. In 
addition, we performed multivariable logistic regression analyses to 
compare the prevalence of  movement disorders by the presence of  spe-
cific prion disease after accounting for differences in age at presentation 
and disease duration.
Post-hoc group comparisons were conducted by either Wilcoxon 
rank sum test or Fisher’s exact test. The sub-group analysis of  GSS 
and gCJD patients’ prevalence gene type was performed using 
Kruskal–Wallis test or Fisher’s exact test. In addition, we performed 
sensitivity analyses excluding either reports published in non-neuro-
logical journals, without documentation of  cognitive changes or both. 
All statistical analyses were carried out using STATA 15 (StataCorp 
LLC, Texas, USA). P-values less than 5% were considered as statisti-
cally significant results.
Results
A total of  275 articles yielded 326 patients for analysis. As only two 
case reports of  VPSPr fulfilled our criteria, their data were not included. 
The most frequent phenotype was sCJD (50.6% of  total cases), followed 
by GSS (15.4%), gCJD (13.9%), FFI (9.3%), vCJD (7.1%), and iCJD 
(3.7%).
Disease onset and symptom course
The age of  onset was different between groups. The median age of  
onset for sCJD and gCJD was about 60 years, while the median for the 
other prionopathies was below 50 years. Sporadic CJD had the highest 
median age of  onset (62 years, p < 0.001) and vCJD has the lowest 
median age (36 years p < 0.001) (Table 1). The course of  disease was 
longer in GSS (median, 58.5 months) compared to the other prionopa-
thies (p < 0.001) and shorter in gCJD (5 months; p < 0.001) (Table 1).
The timing of  symptom onset (i.e., cognitive/behavioral, movement 
disorders, dysautonomia, or sleep disturbances) differed between 
groups. Cognitive/behavioral symptoms were part of  the initial presen-
tation in more than half  of  all prionopathies except for FFI, in which it 
was present at onset in only one third of  cases. Cognitive/behavioral 
symptoms were absent in 18.9% of  cases of  sCJD, a significant differ-
ence from other groups (p < 0.001) (Table 1).
Movement disorders were present at some point in almost all cases 
reviewed and were part of  the initial presentation in more than half  of  
sCJD, iCJD, and GSS cases. Dysautonomia and sleep impairment were 
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more common in FFI patients at onset and during the course of  the 
disease (p < 0.001). No sleep impairments were reported in GSS cases 
(Table 1).
Prevalence of movement disorders
Gait ataxia was the most common movement disorder in all prionop-
athies combined. Indeed, it was the only manifestation reported in 
greater than half  of  all diseases, being most common in vCJD (91.3% 
of  cases; p = 0.01). Gait ataxia was also the most common movement 
disorder in sCJD (62.8% of  cases), iCJD (75% of  cases), and GSS (74% 
of  cases) (Table 2). Myoclonus was the most frequent movement disor-
der in gCJD and FFI, followed by gait ataxia (Table 2). Except for GSS 
patients, myoclonus was also present in more than half  of  the prionop-
athies (24% of  GSS cases, p < 0.001) (Table 2).
Chorea was the least frequent movement disorder encountered in pri-
onopathies, reported in only 15 cases, disproportionally clustering in 
vCJD (47% of  cases; p < 0.001). Dystonia was also uncommon but, when 
present, more often associated with sCJD (75% of  cases; p = 0.036).
Parkinsonism and isolated rigidity were least common in sCJD (7.3%, 
p = 0.043) and FFI (23.3%, p = 0.034) compared to other prionopa-
thies, respectively. GSS had a lower prevalence of  limb ataxia (20% of  
cases; p = 0.004) compared to other prionopathies. Gaze palsy was seen 
in just over 10% of  sCJD (Table 2). The results reported in this section 
did not change after adjusting for age at onset and duration of  disease 
neither after performing sensitivity analyses (Supplementary Tables 1–9)
Time from movement disorder onset until death
The time of  movement disorder onset until death varied across diseases, 
being shorter in sCJD compared with other prionopathies for gait ataxia 
(5 months; p = 0.014), myoclonus (2 months; p < 0.001), parkinsonism 
(3 months; p = 0.024) and isolated rigidity (5.5 months; p = 0.018). The 
respective durations of  gait ataxia (56 months; p < 0.001), limb ataxia 
(58.5 months; p < 0.001), parkinsonism (36 months; p < 0.001), and rigidity 
(42 months; p < 0.001) were longer in GSS compared with other prionop-
athies (Table 3). When compared to disease duration, gait and limb ataxia 
appeared as early features in the course of  sCJD and GSS, whereas 
Table 1.  Clinical and Demographic Features of  Human Prionopathies in the Published Literature
N sCJD vCJD iCJD gCJD FFI GSS p
N (%) N (%) N (%) N (%) N (%) N (%)
164 23 12 45 30 50
Age at onset (y), median (IQR) 62 (54, 69) 36 (26, 41) 45.5 (37, 52.5) 60 (46, 68) 45 (34, 53) 48 (37, 56) <0.001
Disease duration (m), median (IQR) 7 (4, 15.5) 17 (10, 18) 9.5 (6.5, 12) 5 (4, 16) 11 (9, 13) 58.5 (30, 96) <0.001
Cognitive/Behavioral <0.001
 Onset 95 (57.9%) 18 (78.3%) 8 (66.7%) 34 (75.6%) 10 (33.3%) 29 (58%)
 Later in course 38 (23.2%) 4 (17.4%) 4 (33.3%) 9 (20%) 18 (60%) 16 (32%)
 Not reported 31 (18.9%) 1 (4.3%) 0 (0%) 2 (4.4%) 2 (6.7%) 5 (10%)
Movement Disorders <0.001
 Onset 89 (54.3%) 6 (26.1%) 8 (66.7%) 14 (31.1%) 10 (33.3%) 30 (60%)
 Later in course 73 (44.5%) 17 (73.9%) 4 (33.3%) 30 (66.7%) 20 (46.7%) 18 (36%)
 Not reported 2 (1.2%) 0 (0%) 0 (0%) 1 (2.2%) 0 (0%) 2 (4%)
Dysautonomia <0.001
 Onset 0 (0%) 0 (0%) 0 (0%) 0 (0%) 5 (16.7%) 0 (0%)
 Later in course 1 (0.6%) 0 (0%) 1 (8.3%) 7 (15.6%) 16 (53.3%) 0 (0%)
 Not reported 163 (99.4%) 23 (100%) 11 (91.7%) 38 (84.4%) 9 (30%) 50 (100%)
Sleep disorder <0.001
 Onset 2 (1.2%) 0 (0%) 1 (8.3%) 7 (15.7%) 19 (63.3%) 0 (0%)
 Later in course 1 (0.6%) 0 (0%) 0 (0%) 5 (10%) 8 (26.6%) 0 (0%)
 Not reported 161 (98.2%) 23 (100%) 11 (91.7%) 33 (73.3%) 3 (10%) 50 (100%)
Abbreviations: FFI, Fatal Familial Insomnia; gCJD, Genetic Creutzfeldt–Jakob Disease; GSS, Gerstmann–Sträussler–Scheinker Disease; iCJD, 
Iatrogenic Creutzfeldt–Jakob Disease; IQR, Interquartile Range; p-value, Wilcoxon rank sum test for continuous data and chi-square test for 
categorical data; sCJD, Sporadic Creutzfeldt–Jakob Disease; vCJD, Variant Creutzfeldt–Jakob Disease.
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myoclonus appeared in the middle stages of  these diseases, a feature 
observed in sCJD and other prionopathies (Supplementary Table 1).
Clinical features of gCJD due to E200K mutation
While gCJD is most often due to E200K mutations in the PRNP gene, 
other genetic PRNP mutations have been identified as causative. 
Compared to other nine mutations associated with gCJD, carriers of  the 
E200K mutation had a shorter disease course (4 months) compared to 
carriers of  other mutations (12 months) (p < 0.001). In addition, E200K 
PRNP carriers presented more often with autonomic (p = 0.015) and 
sleep changes (p = 0.019). Gait and limb ataxia were more common in 
E200K compared to other mutation carriers (p < 0.001). Parkinsonism 
was not reported in E200K carriers, whereas it was present in almost a 
third of  non-E200K mutations (p = 0.016) (Table 4).
Clinical features of GSS due to P102L mutation
Multiple mutations to the PRNP gene have been associated with 
GSS, with P102L being the most common. Movement disorders were 
more often seen as the initial presentation in subjects with P102L muta-
tions compared to those with the other nine mutations associated with 
GSS (p = 0.047). Except for parkinsonism being more common in non-
P102L carriers compared to P102L carrier (41% of  cases vs. 6%, 
p-value = 0.004), there were no significant differences in the presenta-
tion or duration of  symptoms (Table 5).
Table 2.  Prevalence of  Movement Disorders in Human Prionopathies
N sCJD vCJD iCJD gCJD FFI GSS p-value
N(%) N(%) N(%) N(%) N(%) N(%)
164 23 12 45 30 50
Gait ataxia 103 (62.8%) 21 (91.3%) 9 (75%) 30 (66.7%) 17 (56.7%) 37 (74%) 0.051
Limb ataxia 66 (40.2%) 9 (39.1%) 7 (58.3%) 24 (53.3%) 8 (26.7%) 10 (20%) 0.012
Myoclonus 96 (58.5%) 13 (56.5%) 8 (66.7%) 32 (71.1%) 20 (66.7%) 12 (24%) <0.001
Tremor 8 (4.9%) 2 (8.7%) 1 (8.3%) 3 (6.7%) 4 (13.3%) 4 (8%) 0.47
Parkinsonism 12 (7.3%) 2 (8.7%) 1 (8.3%) 7 (15.6%) 4 (13.3%) 9 (18%) 0.24
Rigidity 72 (43.9%) 7 (30.4%) 3 (25%) 26 (57.8%) 7 (23.3%) 20 (40%) 0.037
Chorea 6 (3.7%) 7 (30.4%) 0 (0%) 0 (0%) 0 (0%) 2 (4%) <0.001
Dystonia 15 (9.1%) 2 (8.7%) 0 (0%) 1 (2.2%) 0 (0%) 2 (4%) 0.28
Gaze palsy 18 (11%) 3 (13%) 1 (8.3%) 1 (2.2%) 0 (0%) 0 (0%) 0.011
Abbreviations: FFI, Fatal Familial Insomnia; gCJD, Genetic Creutzfeldt–Jakob Disease; GSS, Gerstmann–Sträussler–Scheinker Disease; 
iCJD, Iatrogenic Creutzfeldt–Jakob Disease; p-value, Fisher’s exact test; sCJD, Sporadic Creutzfeldt–Jakob Disease; vCJD, Variant 
Creutzfeldt–Jakob Disease.
Table 3.  Time (Months) from Movement Disorder Onset until Death
sCJD vCJD iCJD gCJD FFI GSS p-value
Gait ataxia, median (IQR) 5 (2, 12) 8 (6, 18) 7 (6, 8) 4.5 (4, 10) 9 (5, 12) 56 (13, 84) <0.001
Limb ataxia, median (IQR) 4 (2, 12) 7 (6, 18) 6 (4, 13) 5 (3, 9.5) 5.5 (3.5, 18.5) 58.5 (48, 72) 0.017
Myoclonus, median (IQR) 2 (2, 4.5) 6 (3, 12) 4.5 (2, 9) 4 (2, 10) 5 (3, 8) 5.5 (2.5, 71) 0.025
Tremor, median (IQR) 3 (1.5, 7) 23.5 (12, 35) 10 (10, 10) 4 (4, 60) 9.5 (5, 13) 31.5 (2, 84) 0.57
Parkinsonism, median (IQR) 3 (3, 13.5) 4.5 (1, 8) 10 (10, 10) 18 (16, 90) 8.5 (5.5, 18) 36 (24, 65) 0.100
Rigidity, median (IQR) 5.5 (2, 12.5) 17 (7, 18) 13 (8, 13) 5 (4, 16) 9 (5, 17) 42 (9.5, 102) 0.002
Chorea, median (IQR) 14 (4, 27) 3 (2, 8) - - - 2. (2, 3) 0.12
Dystonia, median (IQR) 2 (2, 6) 14.5 (11, 18) - 3 (3, 3) - 60.5 (1, 120) 0.48
Gaze palsy, median (IQR) 8.5 (2, 14) 8 (7, 14) 13 (13, 13) 16 (16, 16) - - 0.71
Abbreviations: FFI, Fatal Familial Insomnia; gCJD, Genetic Creutzfeldt–Jakob Disease; GSS, Gerstmann–Sträussler–Scheinker Disease; 
iCJD, Iatrogenic Creutzfeldt–Jakob Disease; IQR, Interquartile Range; p-value, Wilcoxon rank sum test; sCJD, Sporadic CJD; vCJD, 
Variant Creutzfeldt–Jakob Disease.
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Discussion
In this systematic review, we evaluated the prevalence of  movement 
disorders in prionopathies and their timing of  presentation. To our 
knowledge, this is the first systematic assessment of  movement disorders 
in all human prionopathies. The age of  onset was older (over 60) in 
sCJD and gCJD compared with other prionopathies (under 50). Gait 
ataxia was the most common movement disorder, noted in more than 
half  of  all prionopathies; limb ataxia was, however, uncommon in GSS 
and FFI (20 and 25%) compared to other prionopathies. Myoclonus 
was common but appeared later in all prionopathies; chorea was 
uncommon but disproportionately prevalent in vCJD. In terms of  
gCJD, E200K PRNP carriers had a shorter disease course, more sleep 
disturbances, and dysautonomia at onset compared to other gCJD 
mutation carriers. Not surprisingly, sleep disorders were the most com-
mon presentation in FFI.
As previously reported, patients with GSS had a significantly longer 
median disease duration (58.5 months) compared to those with other 
prionopathies.1 Thus, GSS should be considered a chronic, rather than 
a subacute, progressive disorder. Previous studies suggested that cogni-
tive and behavioral symptoms were more common in sCJD, whereas 
Table 4.  Difference in Clinical Features in gCJD with and without E200K Mutation
gCJD E200K+(n = 19) gCJD E200K-(n = 26) p-value
Age at presentation (years), median (IQR) 54 (46, 64) 60.5 (47, 73) 0.32
Total disease duration (months), median (IQR) 4 (2, 5) 12 (4, 22) <0.001
Cognitive/Behavioral 0.15
 Initial presentation, N (%) 12 (63%) 22 (85%)
 Later in course, N (%) 6 (32%) 3 (11%)
 Not reported, N (%) 1 (5%) 1 (4%)
Movement Disorders 0.35
 Initial presentation, N (%) 8 (42%) 6 (23%)
 Later in course, N (%) 11 (58%) 19 (73%)
 Not reported, N (%) 0 (0%) 1 (4%)
Dysautonomia 0.015
 Initial presentation, N (%) 0 (0%) 0 (0%)
 Later in course, N (%) 4 (21%) 2 (8%)
 Not reported, N (%) 15 (79%) 24 (92%)
Sleep disorder 0.019
 Initial presentation, N (%) 6 (32%) 1 (4%)
 Later in course, N (%) 0 (0%) 3 (11%)
 Not reported, N (%) 13 (68%) 22 (85%)
Presence of  movement disorders
 Gait ataxia, N (%) 18 (95%) 12 (46%) <0.001
 Limb ataxia, N (%) 16 (84%) 8 (31%) <0.001
 Myoclonus, N (%) 14 (74%) 18 (69%) 1.00
 Tremor, N (%) 0 (0%) 3 (11%) 0.25
 Parkinsonism, N (%) 0 (0%) 7 (27%) 0.016
 Rigidity, N (%) 13 (68%) 13 (50%) 0.24
 Chorea, N (%) 0 (0%) 0 (0%)
 Dystonia, N (%) 1 (5%) 0 (0%) 0.42
 Gaze palsy, N (%) 0 (0%) 1 (4%) 1.00
Abbreviations: gCJD, Genetic Creutzfeldt–Jakob Disease; IQR, Interquartile Range; p-value, Wilcoxon rank sum test for continuous data and 
Fisher’s exact test for categorical data.
E200K- group included the following mutations to the PRNP gene, E196K; D178N/129V; G114K; M232R; P105T; R208H; T183A; 
T188R and V180I.
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movement disorders, specifically gait ataxia, were most common as ini-
tial features in GSS.1,2 However, in this systematic review, cognitive/
behavioral symptoms and movement disorders were similar in fre-
quency at the onset of  sCJD, iCJD, and GSS. Cognitive and behavioral 
changes were markedly more common at onset in vCJD and gCJD 
compared to other prionopathies. Indeed, the initial manifestation with 
behavioral abnormalities is a well-known feature of  vCJD.3
Cerebellar degeneration is typically considered the neuroanatomical 
substrate of  gait and limb ataxia in the prionopathies. However, ataxia 
may also be exceptionally contributed to by myelopathy, peripheral neu-
ropathy, or frontal lobe impairment.4,5 Gait ataxia has been reported as 
common in sCJD and GSS.1,6 Isolated gait ataxia presenting years to 
decades before the onset of  cognitive symptoms has been described as a 
characteristic feature of  the VV2 (ataxic) subtype of  sCJD, and in mis-
sense mutations causing GSS.7,8 However, while gait ataxia was 
common in GSS, our results showed limb ataxia was less common com-
pared to other prionopathies. The nature of  this discrepancy can be 
attributed to the degeneration of  the spinocerebellar tracts and the pos-
terior horn of  the spinal cord as the main driver of  symptoms of  GSS 
rather than cerebellar degeneration.9,10 In addition, the presence of  gait 
and limb ataxia early in the disease course may be suggestive of  gCJD 
due to an E200K mutation.11,12 Although not common at presentation, 
almost all vCJD patients manifest gait ataxia at some point during the 
disease.3,13
The presence of  myoclonus in the context of  cognitive impairment is 
often associated with sCJD, justifying its inclusion in most diagnostic 
criteria.14–16 In sCJD, spontaneous myoclonus presents as distal and sym-
metric in the hands, becoming generalized later in the disease. However, 
asymmetric stimulus-sensitive myoclonus has also been described.17 The 
latter is reminiscent of  a startle response but can be distinguished from 
Table 5.  Difference in Clinical Features in GSS with and without P102L Mutation
GSS P102L+(n = 33) GSS P102L-(n = 17) p-value
Age at presentation (y), mean (IQR) 50 (38, 56) 47 (37, 60) 0.67
Total disease duration ( s), mean (IQR) 56 (30, 84) 72 (30, 120) 0.47
Cognitive/Behavioral 0.059
 Initial presentation, N (%) 16 (49%) 13 (76%)
 Later in course, N (%) 13 (39%) 3 (18%)
 Not reported, N (%) 4 (12%) 1 (6%)
Movement Disorders 0.047
 Initial presentation, N (%) 23 (70%) 7 (41%)
 Later in course, N (%) 8 (24%) 10 (59%)
 Not reported, N (%) 2 (6%) 0 (0%)
Dysautonomia
 Not reported N (%) 33 (100%) 17 (100%)
Sleep disorder
 Not Reported N (%) 33 (100%) 17 (100%)
Movement disorders
Gait ataxia, N (%) 26 (79%) 11 (65%) 0.32
Limb ataxia, N (%) 6 (18%) 4 (24%) 0.72
Myoclonus, N (%) 5 (15%) 7 (41%) 0.077
Tremor, N (%) 2 (6%) 2 (12%) 0.60
Parkinsonism, N (%) 2 (6%) 7 (41%) 0.004
Rigidity, N (%) 11 (33%) 9 (53%) 0.23
Chorea, N (%) 1 (3%) 1 (6%) 1.00
Dystonia, N (%) 0 (0%) 2 (12%) 0.11
Gaze palsy, N (%) 0 (0%) 0 (0%)
Abbreviations: GSS, Gerstmann–Sträussler–Scheinker Disease; IQR, Interquartile Range; p-value, Wilcoxon rank sum test for continuous data 
and Fisher’s exact test for categorical data.
P102L-group included the following mutations to the PRNP gene: A117V, D202N, G131V, H187R, P84S, Q212P, Q217R, 6 and 7 
octapeptide repeat insertions.
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it by the presence of  habituation.18 Although myoclonus is a common 
feature in sCJD, it appears in the mid-to-late stages in this and other 
prionopathies. Myoclonus is rare in GSS.
Other movement disorders were less frequently observed but their 
presence may help inform the differential diagnosis. Although chorea 
was rarely reported, almost half  of  the cases with chorea were associ-
ated with vCJD, and thus, this diagnosis should be considered in the 
differential diagnosis of  Huntington disease.3,19 The presence of  move-
ment disorders in vCJD has been associated with the degeneration of  
cholinergic neurons in the caudate and putamen.20 In the sporadic 
form, although less frequent, the duration of  chorea was longer (14 
months) than the median duration of  the disease (7 months), which may 
suggest a longer survival in those who present with chorea. Patients with 
GSS had the longest disease duration overall, but the median duration 
of  chorea was only 2.5 months, suggesting that when present, chorea 
may represent a late feature.
Finally, gaze palsy is rarely reported but likely to be under-recog-
nized. We found the presence of  gaze palsy to be more often associated 
with sCJD. However, limitations in upgaze and slowness of  saccades are 
often present in vCJD and have been reported as early findings in 
iCJD.21,22 These abnormalities usually progress to further affect eye 
movements, leading to ophthalmoparesis.23 Gaze limitations are also 
described in gCJD and GSS as a later manifestation.23,24 Other oculo-
motor abnormalities include impaired pursuit and nystagmus.23
The classification of  prionopathies is based on the morphology of  
the PrP and amyloid deposition.25 PrP deposition is often associated 
with a pattern of  neurodegeneration in which certain structures are 
more predisposed to damage or selectively vulnerable depending on the 
PrP conformation.26 PrP predominantly affects cerebral cortical struc-
tures in sCJD; the anterior and medial nuclei of  the thalamus in FFI; 
the medial and posterior thalamus as well as the striatum, neocortex, 
and cerebellum in vCJD; and the cerebellum and spinal cord and, to a 
lesser extent, the neocortex in GSS.8,13,27,28 This selectivity decreases as 
PrP spreads to other areas toward later phases. These correlations are 
not precise and there are multiple factors affecting the spread of  the 
prion pathology, which could explain the varied presentation. The most 
prominent example is sCJD, in which the different phenotypes (e.g., cor-
tical, cerebellar, and thalamic variants) depended on the areas of  pre-
dominant degeneration.29 The differences in the patterns of  
neurodegeneration and associated clinical presentations are modulated 
by the combination of  the variability of  methionine/valine polymor-
phism at codon 129 in the PRNP (MV, MM, VV) and the electropho-
retic pattern of  PrP after exposure of  prion protein to proteinase K 
digestion (classified as 1 or 2) (Table 6).30 While MM1 and MV1 vari-
ants are more likely to exhibit rapidly progressive dementia with multi-
system neurological disorder, the VV2 (cerebellar) variant accounts for 
the second most common subtype and it is almost invariably associated 
with a cerebellar syndrome at the onset, without preceding cognitive 
changes.5,7 Further understanding of  anatomical underpinnings of  
movement disorders in prionopathies and the factors affecting the selec-
tive vulnerability will have an impact on diagnosis, prognosis, and 
potential treatment.
These conclusions have to be tempered by a number of  limitations 
when considering their applicability to clinical practice. First, the 
Table 6.  Subtypes of  Sporadic Creutzfeldt–Jakob Disease
Subtype* (frequency) Age of  onset 
Years (range)
Duration 
Months (range)
Presentation Movement  
disorders
Regions predominantly 
affected
MM1/MV1(65%) 68 (31–86) 5 (1–24) Cognitive/
behavioral, visual 
changes
Ataxia Myoclonus Neocortex (particularly 
occipital lobe), 
subcortical nuclei and 
cerebellum
VV2(20%) 64 (40–83) 6.5 (3–18) Cerebellar 
dysfunction. Later, 
cognitive/behavioral 
changes
Gait and limb 
ataxia Oculomotor 
abnormalities
Cerebellum and 
subcortical nuclei
MV2(10%) 65 (36–83) 17 (4–48) Cognitive/
behavioral or motor
Ataxia Parkinsonism 
Myoclonus
Cerebellum and 
subcortical nuclei. Less 
cortical involvement
MM2 (Thalamic)(<5%) 52 (26–71) 16 (8–36) Insomnia, cognitive Ataxia Myoclonus Thalamus and inferior 
olive
MM2 (Cortical)(<5%) 64 (49–77) 16 (9–36) Cognitive, apraxia, 
aphasia
Myoclonus Neocortex
VV1(1%) 44 (19–55) 21 (17–42) Cognitive/
behavioral
Ataxia Parkinsonism Cortex and striatum
*Subtypes are based on the combination of  methionine/valine polymorphism at codon 129 in the PRNP (MV, MM, VV) and the 
electrophoresis pattern of  PrP after the exposure of  prion protein to proteinase K digestion (classified as 1 or 2).
Frequency, age of  onset, and duration values for this table were obtained from literature review.
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selection of  cases with genetic or pathological confirmation aimed for a 
more conservative selection but rendered many reports, mainly of  
sCJD, ineligible for analysis. This point should be considered when 
applying our findings to clinical practice, where patients are more often 
diagnosed based on clinical, imaging, and CSF findings, and only a 
minority have had an autopsy or genetic testing. Second, the reliance on 
reported cases invariably leads to a selection bias, as cases reported often 
need to justify their publication with an element of  novelty, raising the 
concern that the sample is not representative of  the whole of  prionopa-
thies. The presence of  movement disorders is a common reason to pub-
lish a case report, which can lead to their overrepresentation, with 
potential under-representation of  iCJD or vCJD. Reassuringly, the age 
at onset and the duration of  the disease in this study are similar to those 
in prior reports. Third, the nature of  case reports publication requires a 
succinct case presentation highlighting the features of  interest for the 
report, sometimes leaving out details not considered of  interest to the 
publication. This limits the identification of  all the elements in the case 
presentation and may in part explain the absence of  documented cog-
nitive or behavioral changes in up to 20% of  sCJD reports. However, 
our sensitivity analyses performed by excluding reports without the 
mention of  cognitive changes or those not published in neurology jour-
nals did not affect our results. It should also be noted that most of  these 
case reports were not accompanied by video material, and thus, the phe-
nomenology, which may have been described by non-movement disor-
ders specialists, cannot be confirmed. In addition, we did not include 
abnormalities not currently classified as movement disorders, such as 
spasticity and alien hand syndrome, which have also been reported in 
prionopathies.31 Finally, our study aimed to report the onset of  symp-
toms relative to the time to death. While this measure can help under-
stand the progression of  the disease, it may be misleading as the sole 
marker of  disease duration. It should also be noted that this analysis was 
limited to the onset of  symptoms but did not take into account whether 
the movement disorders remained present until death. In addition, 
while the analysis of  the symptom/disease duration ratio can be helpful 
to understand the progression of  the individual prionopathy, the total 
duration of  each disease needs to be accounted for when translating it 
to the differential diagnosis of  prionopathies. One solution to the limita-
tions of  our review, due to the heterogeneity of  the reported clinical 
characteristics, could be a prospective study, with a standardized form to 
document clinical features as the disease progressed, which could be 
implemented in any case where the diagnosis is suspected. Despite these 
limitations, this is the first comprehensive systematic review to evaluate 
the prevalence and duration of  movement disorders in prionopathies, 
and the results reported can help guide the evaluation of  suspected 
prionopathies.
Conclusion
In conclusion, movement disorders are common in prionopathies, 
with differential appearance of  specific movements in the various disor-
ders. The differences in phenomenology and duration may result from 
selective neuronal and network vulnerability. A prospective epidemio-
logic study would be desirable to further refine the clinical variables that 
may affect the frequency, type, onset, and duration of  movement disor-
ders in prionopathies.
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